IFEOMA ARENE: Open Payments
NPI 1780642488 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,115 in 123 payments from 19 companies in 2025. Trend: 2023 $2,016 · 2024 $2,137 · 2025 $2,115
Food & beverage: $2,115
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 22 | $412 |
| Neurocrine BioSciences, Inc. | 12 | $234 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $203 |
| ABBVIE INC. | 13 | $198 |
| Alkermes, Inc. | 18 | $188 |
| Indivior Inc. | 7 | $171 |
| Lundbeck LLC | 9 | $145 |
| Tris Pharma Inc | 9 | $135 |
| Axsome Therapeutics, Inc. | 4 | $117 |
| Corium, LLC | 5 | $74 |
Products named: REXULTI, INGREZZA, CAPLYTA, VRAYLAR, SUBLOCADE, ARISTADA, Auvelity, Dyanavel XR.
Industry payments across TX — which companies pay providers there.
